About
Soligenix Inc (NASDAQ:SNGX) — investor relations, events, news, and company updates on 6ix.
Latest News
Apr 2 2026
Positive Clinical Results from HyBryte™ Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma Published in Oncology and Therapy
Mar 31 2026
Soligenix Announces Recent Accomplishments and Year End 2025 Financial Results
Mar 26 2026
Soligenix Receives Orphan Drug Designation from the European Commission for SGX945 for the Treatment of Behçet's Disease
Mar 24 2026
Soligenix (SNGX) HyBryte Data To Be Presented At USCLC Workshop Ahead Of AAD Meeting
Mar 23 2026
HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026
Google Übersetzer